Our executive team is charged with the early development of GAFFI and additional members will join this start up team.
David Denning is an internationally recognised clinician with expertise in fungal diseases. He manages the UK’s National Aspergillosis Centre in Manchester, the world’s only such centre. David Denning has published more than 500 papers, books and book chapters and lectures worldwide. His writings have been cited over 40,000 times and he has successfully lead many major international collaborative science, diagnostic and treatment projects and clinical guidelines, with subsequent publication in Nature, the New England Journal of Medicine and the Lancet. He is the Founder of two University spinout biotechnology companies – F2G Ltd (antifungal drug discovery and development) and Myconostica Ltd (molecular diagnostic tests for fungi), now owned by Lab21.
David is Chairman of the Editorial Board of The Aspergillus Website (1998-) with over 1 million pages read per month. He has chaired the Scientific Committees of several international fungal infection meetings and co-chairs the alternate year Advances Against Aspergillosis meetings, attracting ~400 delegates from >120 countries.
Dr Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company, in Novocyt which markets the Myconostica real-time molecular assays. He acts or has recently acted as a consultant to Astellas, Sigma Tau, Basilea, Scynexis, Cidara, Biosergen, Quintilles and Pulmocide. In the last 3 years, he has been paid for talks on behalf of Astellas, Dynamiker, Gilead, Merck and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group and the British Society for Medical Mycology Standards of Care committee.
David is a Swiss Board member and a Trustee of GAFFI, UK
Tim Moss is an accountant who oversees the finances and governance for GAFFI and GAFFi UK. Tim qualified as a chartered accountant with Pannell Kerr Forster in London in 1990 and has over 30 years experience having held senior financial positions with a number of private and public companies in financial services, utilities, food product development, communications and telecoms sectors. He has been based in Geneva, Switzerland, since May 2006.
He has wide ranging commercial experience, developing strategies, financial reporting, audit and corporate governance to meet statutory and stakeholder expectations. Considerable experience managing, developing and implementing processes designed for rapidly expanding enterprises including budgeting¸ cash flow and fund raising.
Felix Bongomin is an early career physician with clinical and research interests in fungal diseases. Felix was born and raised in northern Uganda during the brutal Lord’s Resistance Army civil war that lasted for over 20 years and was characterised by brutal attacks against civilians as well as the widespread abduction of children. He received his primary and secondary education in northern Ugandan districts of Kitgum and Gulu and a medical degree from Gulu University.
Felix received an Equity and Merit scholarship from the University of Manchester to study a Master of Science (M.Sc.) degree in Medical Mycology. He completed and graduated with his M.Sc. in 2016.
Felix joined GAFFI in early 2017 as a clinical research associate in-charge of antifungal access program and fungal disease education. He has an on-going responsibility of preparing educational materials in all aspects of a number of fungal diseases and antifungal agents. He contributes to the Leading International Fungal Education (LIFE) portal and is actively involved in service evaluation/clinical audits at the UK’s National Aspergillosis Centre based at Wythenshawe Hospital.
Jenny has been Senior Editor and Writer for the Aspergillus Web educational resources for the past 15 years. She previously worked in Oncology research at Christie’s Hospital, Manchester and on Rheumatoid arthritis at Manchester University and as Lecturer at Monash University, Melbourne.
Her expertise encompasses all aspects of fungal diseases working within the University Hospital of South Manchester and also the National Aspergillosis Centre. Jenny launched the LIFE-worldwide website in 2012 and then GAFFI in 2013; she continues her role as communications director and editor in chief for GAFFI as it continues to develop.
Elizabeth Peers has worked in clinical drug development since 1983, starting at AstraZeneca, initially in respiratory and cardiovascular phase 3/4 development before moving to gastrointestinal (omeprazole). She followed this with 17 years working in small pharma and biotech companies on drug, biologic and device development, in respiratory, renal, oncology, gene therapy, surgery and pain. This work encompassed phase 1,2 and 3 with successful regulatory approvals in Europe and USA. Several projects included re-engineering established drugs for new indications via different routes of delivery.
Elizabeth rejoined big pharma (Sanofi) in 2007, first in Phase 1 and then in a strategic unit for diseases of aging, as a Clinical Expert in Translational Medicine designing decision-making Paths to Proof of Concept for new compounds with novel mechanisms of action. She now offers strategic advice through selected partnerships including The Research Network (TRN) in an independent capacity.
Elizabeth Peers holds a master’s degree in Natural Sciences (Pharmacology) from the University of Cambridge, a doctorate in Physiological Biochemistry from Imperial College London, and a diploma in Company Direction from Loughborough Business School. She has worked in multicultural teams and is well acquainted with differing cultural attitudes and practices, and is fluent in French.